Cannon, CP; Perkovic, V; Agarwal, R; Baldassarre, J; Bakris, G; Charytan, DM; De Zeeuw, D; ... Mahaffey, KW; + view all Cannon, CP; Perkovic, V; Agarwal, R; Baldassarre, J; Bakris, G; Charytan, DM; De Zeeuw, D; Edwards, R; Greene, T; Heerspink, HJL; Jardine, MJ; Levin, A; Li, J-W; Neal, B; Pollock, C; Wheeler, DC; Zhang, H; Zinman, B; Mahaffey, KW; - view fewer (2020) Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial. Circulation , 141 (5) pp. 407-410. 10.1161/CIRCULATIONAHA.119.044359.

Preview

Text Wheeler CREDENCE HbA1c subgroup research letter CIRCULATION - revised track changes_JGL-67352 as resubmitted.pdf - Accepted Version Download (1MB) | Preview

Abstract

Traditional management of diabetes mellitus has focused on glycemic control, beginning with lifestyle changes, followed by metformin, and then other classes of antiglycemic agents.1 Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce cardiovascular (CV) events, including CV death, myocardial infarction (MI) and heart failure, and slow progression of renal dysfunction, including prevention of end-stage kidney disease (ESKD).2-3 Because initial clinical trials included mostly patients with baseline HbA1c >7%, current guidelines have recommended this class as add-on therapy for patients whose HbA1c is not at goal, typically ≥7%.1 We hypothesized that there would be similar benefits on CV and renal endpoints regardless of baseline HbA1c, including those with HbA1c <7%.

Download activity - last month

Export as XMLJSONCSV

Download activity - last 12 months

Export as CSVXMLJSON

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item